Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-01-09FDA Approved: FLUOXETINE — Supplemental Application (Vensun Pharmaceuticals, Inc.)
FDA approved a supplemental application for fluoxetine hydrochloride from Vensun Pharmaceuticals, Inc., granting approval of a generic fluox…
-
FDA approval · 2024-01-08FDA Approved: CITALOPRAM — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Citalopram by Amneal Pharmaceuticals LLC, indicating approval of a generic Citalopram product un…
-
FDA approval · 2024-01-03FDA Approved: VILAZODONE HYDROCHLORIDE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for vilazodone hydrochloride (Alembic Pharmaceuticals Limited).
-
FDA approval · 2024-01-03FDA Approved: VILAZODONE HYDROCHLORIDE — Supplemental Application (Exelan Pharmaceuticals Inc.)
FDA approved a supplemental application for vilazodone hydrochloride, filed by Exelan Pharmaceuticals Inc. This indicates a supplemental app…
-
FDA approval · 2024-01-03FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for venlafaxine hydrochloride from Aurobindo Pharma Limited, confirming approval of the generic prod…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-01-03FDA Approved: FLUOXETINE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for fluoxetine hydrochloride.
-
FDA approval · 2024-01-03FDA Approved: VILAZODONE HYDROCHLORIDE — Supplemental Application (Northstar Rx LLC)
The FDA approved Northstar Rx LLC's supplemental application for vilazodone hydrochloride, enabling the generic product to be marketed.
-
FDA approval · 2023-12-19FDA Approved: FLUOXETINE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for fluoxetine by Alembic Pharmaceuticals Limited.
-
FDA approval · 2023-12-19FDA Approved: DULOXETINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for duloxetine hydrochloride from Aurobindo Pharma Limited, granting regulatory clearance for a gene…
-
FDA approval · 2023-12-06FDA Approved: MIRTAZAPINE — Supplemental Application (SQUARE PHARMACEUTICALS LIMITED)
FDA approved a supplemental application for mirtazapine from Square Pharmaceuticals Limited.
-
FDA approval · 2023-11-21FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for venlafaxine hydrochloride extended-release (Chartwell RX, LLC), reflecting an approved update to…
-
FDA approval · 2023-11-21FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Granules Pharmaceuticals Inc.)
The FDA approved a supplemental application for venlafaxine hydrochloride from Granules Pharmaceuticals Inc., authorizing an additional form…
-
FDA approval · 2023-11-20FDA Approved: CITALOPRAM HYDROBROMIDE — Supplemental Application (Glenmark Therapeutics Inc., USA)
FDA approved Glenmark Therapeutics’ supplemental application for Citalopram Hydrobromide as a generic antidepressant. Citalopram hydrobromid…
-
FDA approval · 2023-11-20FDA Approved: FLUOXETINE — Supplemental Application (Endo USA, Inc.)
The FDA approved a supplemental application for fluoxetine submitted by Endo USA, Inc., resulting in regulatory changes to the product's sta…
-
FDA approval · 2023-11-15FDA Approved: FLUOXETINE — Supplemental Application (Micro Labs Limited)
FDA approved a supplemental application for fluoxetine (generic) from Micro Labs Limited under an ANDA.
-
FDA approval · 2023-11-01FDA Approved: DESVENLAFAXINE — Supplemental Application (Slate Run Pharmaceuticals, LLC)
FDA approved a supplemental application for desvenlafaxine submitted by Slate Run Pharmaceuticals, LLC, updating the regulatory status of th…
-
FDA approval · 2023-11-01FDA Approved: VENLAFAXINE — Supplemental Application (Zydus Lifesciences Limited)
FDA granted supplemental approval for venlafaxine from Zydus Lifesciences Limited, signaling an approved modification to an existing generic…
-
FDA approval · 2023-11-01FDA Approved: ARIPIPRAZOLE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' generic oral aripiprazole under an original ANDA.
-
FDA approval · 2023-10-30FDA Approved: CITALOPRAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for citalopram hydrobromide from Aurobindo Pharma Limited.
-
FDA approval · 2023-10-23FDA Approved: BUPROPION HYDROCHLORIDE XL — Supplemental Application (Epic Pharma, LLC)
FDA approved a supplemental application for Bupropion hydrochloride extended-release (XL), manufactured by Epic Pharma, LLC.
-
FDA approval · 2023-10-06FDA Approved: IMIPRAMINE HYDROCHLORIDE — Supplemental Application (Leading Pharma, LLC)
The FDA approved a supplemental application for imipramine hydrochloride from Leading Pharma, LLC under the ANDA process.
-
FDA approval · 2023-09-22FDA Approved: EXXUA — Original Application (Aytu Therapeutics, LLC)
The FDA approved EXXUA (gepirone) as a new drug for major depressive disorder.
-
FDA approval · 2023-09-22FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Granules Pharmaceuticals Inc.)
FDA approved a supplemental application for sertraline hydrochloride from Granules Pharmaceuticals Inc. The action confirms continued approv…
-
FDA approval · 2023-09-21FDA Approved: CLOMIPRAMINE HYDROCHLORIDE — Supplemental Application (Lifestar Pharma LLC)
FDA approved a supplemental application for clomipramine hydrochloride from Lifestar Pharma LLC, resulting in a generic version of the antid…
-
FDA approval · 2023-09-19FDA Approved: FLUOXETINE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for fluoxetine submitted by Aurobindo Pharma Limited. This action updates the regulatory status …